ICMR
Hidradenitis suppurativa
Research center in Spain (Madrid)
Clinical studies in hidradenitis suppurativa
Hidradenitis suppurativa is a chronic inflammatory disease that has a significant impact on the quality of life of those affected. Despite therapeutic advances, there remains a constant need to develop more effective and personalized treatment options.
At ICMR, an international clinical research center based in Madrid, we participate in research projects aimed at improving the understanding and management of this condition through rigorously designed clinical trials.
What is hidradenitis suppurativa?
Hidradenitis suppurativa is a chronic inflammatory skin disease that primarily affects areas with apocrine sweat glands, such as the armpits, groin, buttocks, and under the breasts.
It is characterized by the recurrent appearance of:
- Painful inflammatory lesions.
- Deep abscesses.
- Fistulas and permanent scarring.
The exact cause is not fully understood, but it is believed to involve immune system dysfunction, genetic predisposition, and environmental triggers.
Hidradenitis suppurativa is not merely a skin issue—it has systemic implications and has been associated with other inflammatory diseases such as arthritis, Crohn’s disease, metabolic syndrome, and depression.
The severity of the disease varies greatly between patients, and treatment must be tailored individually according to the clinical stage.
What is a clinical trial?
A clinical trial is a type of clinical study that evaluates the safety, efficacy, and tolerability of new therapeutic options before they are approved for widespread use. Clinical trials follow strictly controlled protocols, approved by ethics committees and supervised by official health authorities, ensuring the rights and protection of all participants.
How are clinical trials in hidradenitis suppurativa conducted?
Clinical trials in hidradenitis suppurativa typically include:
- Phase I: initial safety testing in a small group of participants.
- Phase II: evaluation of efficacy and dose optimization in affected patients.
- Phase III: comparison with existing treatments in a larger group of participants.
- Phase IV: post-marketing studies to expand safety data.
Each study is conducted by a specialized medical team that provides detailed and continuous monitoring of all participants.
Active clinical trials in hidradenitis suppurativa
CONDITION
Hidradenitis suppurativa
Study designed to assess the effectiveness of innovative treatments in people with active hidradenitis suppurativa.
Patients aged 18 years or older
Presence of five or more lesions in at least two different body areas
The ICMR is a leading clinical research center in Europe
Hidradenitis suppurativa research projects
At ICMR, we develop and collaborate on research projects aimed at:
Research new immunomodulatory molecules.
- Evaluate treatments that reduce chronic inflammation and prevent the formation of new lesions.
- To study treatment strategies aimed at the early stages of the disease.
- Improve the quality of life of affected patients.
Our projects are carried out in compliance with the highest standards of clinical, scientific and ethical quality.
Contributions of clinical research in hidradenitis suppurativa.
Clinical research plays a key role in medical progress. Thanks to clinical trials in hidradenitis suppurativa, it is possible to:
- Develop more effective and better-tolerated treatments for both acute and chronic stages.
- Advance the understanding of the immune mechanisms involved in the disease.
- Identify predictive factors of response and personalize treatment.
- Improve understanding of the physical, emotional, and social burden associated with this condition.
These advances help expand management options for hidradenitis suppurativa in future clinical practice, benefiting both current and future patients.
Information on Available Clinical Trials
At ICMR Research, we are currently participating in several clinical studies focused on hidradenitis suppurativa, including:
- New biological treatments targeting key inflammatory molecules.
- Combined therapies aimed at preventing disease progression.
- Studies on new strategies for comprehensive management of pain and inflammation.
Each study has specific eligibility criteria, which may depend on:
- The patient’s age.
- Duration and severity of the disease.
- Previous treatments received.
Important considerations
Before considering participation in a clinical trial, it is essential to keep the following in mind:
- Participation is always voluntary and can be withdrawn at any time without affecting your standard medical care.
- Clinical benefit cannot be guaranteed; investigational treatments may produce variable results.
- All trials are reviewed and approved by ethics committees to ensure participant safety.
Our team provides complete and transparent information so that each person can make a free and informed decision.
Frequently asked questions about clinical trials in hidradenitis suppurativa
Does it cost anything to participate in a clinical study?
No. Treatments and medical follow-ups related to the study are usually covered by the sponsor.
What are the potential risks?
Any investigational treatment may involve certain risks, which will be clearly explained before participation.
Can I withdraw from the study if I choose to?
Yes. Participation is voluntary and can be discontinued at any time, without the need to provide justification.
How is my personal data protected?
Data protection is a priority. All collected information is confidential and managed in accordance with current data protection laws.
Where can I get more information?
If you would like more information about clinical trials in hidradenitis suppurativa at ICMR Research, you can contact our team confidentially:
- Through the contact form on our website.
- Email: info@icmrresearch.com
- Via specialized telephone assistance.
We will respond to all inquiries in a personalized manner, with no obligation and full respect for your confidentiality.
About us
ICMR is a reference center in Spain and Europe dedicated to the research of inflammatory and/or immune-mediated dermatological diseases. Promoted by the Pedro Jaén Foundation, our main objective is to transfer the highest level of science to patients who cannot find a solution to their dermatological problems with currently approved treatments.
Research areas
At ICMR we are prepared to develop research in all dermatological indications, with special attention to:
Psoriasis
We analyze genetic and immune factors to improve the approach to this disease.
Alopecia areata
We investigate the autoimmune basis and new options that stimulate hair growth.
Hidradenitis suppurativa
We analyze genetic and immune factors to improve the approach to this disease.
Atopic dermatitis
We explore the alteration of the skin barrier and the mediators that cause inflammation.
Nodular prurigo
We study the origin of severe itching and seek therapies to alleviate the discomfort.
Vitiligo
We investigate the autoimmune process that affects melanocytes and how to recover pigmentation.
Notalgia paresthetica
We study the neuropathic origin of itching and therapies to control the symptoms.